CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common beta chain of the IL-3, GM-CSF and IL-5 receptors.
Panousis, C., Dhagat, U., Edwards, K.M., Rayzman, V., Hardy, M.P., Braley, H., Gauvreau, G.M., Hercus, T.R., Smith, S., Sehmi, R., McMillan, L., Dottore, M., McClure, B.J., Fabri, L.J., Vairo, G., Lopez, A.F., Parker, M.W., Nash, A.D., Wilson, N.J., Wilson, M.J., Owczarek, C.M.(2016) MAbs 8: 436-453
- PubMed: 26651396 
- DOI: 10.1080/19420862.2015.1119352
- Primary Citation of Related Structures:  
5DWU - PubMed Abstract: 
The β common-signaling cytokines interleukin (IL)-3, granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-5 stimulate pro-inflammatory activities of haematopoietic cells via a receptor complex incorporating cytokine-specific α and shared β common (βc, CD131) receptor ...